GeNeuro launches an offering with a commitment to subscribe by existing shareholders and announces its cash position at December 31, 2023
Geneva, Switzerland, February 1, 2024– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the launch of a private placement of ordinary shares […]